MedTrace Logo

A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3

NCT04524208 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2024-08-13

No results posted yet for this study

Summary

The main objective of this clinical trial represents the evaluation of efficacy of the tyrosine kinase inhibitor Cabozantinib in patients with NEN G3 with a proliferation rate of Ki67 20 - 60%.

Conditions

Interventions

DRUG

Cabozantinib

Cabozantinib is administered orally at the dose of 60 mg per day..

Sponsors & Collaborators

  • Karsten Gavenis

    lead OTHER

Principal Investigators

  • Alexander König, PD Dr. · University Medical Center Göttingen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2024-09-30
Completion
2024-10-31

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04524208 on ClinicalTrials.gov